Menu Search
Equities

MedPlus Health Services Ltd

MEDPLUS:NSI

MedPlus Health Services Ltd

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (INR)704.25
  • Today's Change7.35 / 1.05%
  • Shares traded970.43k
  • 1 Year change-13.48%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 10:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year MedPlus Health Services Ltd grew revenues 23.42% from 45.58bn to 56.25bn while net income improved 31.57% from 497.63m to 654.73m.
Gross margin22.66%
Net profit margin1.67%
Operating margin2.94%
Return on assets3.29%
Return on equity6.35%
Return on investment4.02%
More ▼

Cash flow in INRView more

In 2024, cash reserves at MedPlus Health Services Ltd fell by 1.37bn. However, the company earned 1.44bn from its operations for a Cash Flow Margin of 2.56%. In addition the company used 827.99m on investing activities and also paid 1.98bn in financing cash flows.
Cash flow per share28.35
Price/Cash flow per share24.03
Book value per share136.89
Tangible book value per share132.57
More ▼

Balance sheet in INRView more

MedPlus Health Services Ltd has a Debt to Total Capital ratio of 38.63%, a lower figure than the previous year's 55.42%.
Current ratio3.04
Quick ratio0.6598
Total debt/total equity0.6293
Total debt/total capital0.3863
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 31.16%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
EPS growth(5 years)40.42
EPS (TTM) vs
TTM 1 year ago		71.75
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.